Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus

Código QR

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus

Pamela KushnerUniversity of California, Irvine College of Medicine, California, USAAbstract: Hypoglycemia is a major barrier to achieving glycemic goals in patients with diabetes. Both acute and chronically recurrent hypoglycemic events appear to have long-term consequences for patients with type 2...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Kushner P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Hypoglycemia type 2 diabetes mellitus incretin dipeptidyl peptidase-4 inhibitors diabetes management Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/1eca60a17676493fb776e45358fb1ef9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Saxagliptin for type 2 diabetes
por: Chacra
Publicado: (2010)

Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
por: Wang N, et al.
Publicado: (2019)

Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
por: Lin YH, et al.
Publicado: (2019)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
por: Han E, et al.
Publicado: (2020)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
por: Green J, et al.
Publicado: (2010)

Teneligliptin in management of type 2 diabetes mellitus
por: Sharma SK, et al.
Publicado: (2016)

Association Between Knowledge of Hypoglycemia and Likelihood of Experiencing Hypoglycemia Among Patients with Insulin-Treated Diabetes Mellitus
por: Almigbal TH
Publicado: (2021)

Randomized Study Comparing Vildagliptin vs Glibenclamide on Glucose Variability and Endothelial Function in Patients with Type 2 Diabetes Mellitus and Hypertension
por: Cosenso-Martin LN, et al.
Publicado: (2020)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahren B
Publicado: (2010)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
por: Gagik Radikovich Galstyan, et al.
Publicado: (2015)

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
por: Karyekar CS, et al.
Publicado: (2013)

Adjunctive therapy for glucose control in patients with type 1 diabetes
por: Harris K, et al.
Publicado: (2018)

The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future
por: Juris J. Meier
Publicado: (2019)

The durability of sitagliptin in elderly patients with type 2 diabetes
por: Hsieh CJ, et al.
Publicado: (2014)

Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
por: Ghosh S, et al.
Publicado: (2016)

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
por: Pamela Kushner
Publicado: (2010)

Incretin-based therapy: renal effects
por: Anton Ivanovich Korbut, et al.
Publicado: (2016)

Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach
por: Pollock RF, et al.
Publicado: (2018)

Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease
por: Chen L, et al.
Publicado: (2020)

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
por: Gallwitz B
Publicado: (2010)

Assessing Prevalence of Hypoglycemia in a Medical Transcription Database
por: Uzoigwe C, et al.
Publicado: (2020)

ACE inhibitors as a risk factor for hypoglycemia
por: Andrey Alexeevich Aleksandrov, et al.
Publicado: (2011)

Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
por: Schwartz S
Publicado: (2010)

Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
por: Ahmadieh H, et al.
Publicado: (2017)

Frequency of Diabetic Ketoacidosis and Severe Hypoglycemia in Children with Type 1 Diabetes
por: A Homaei, et al.
Publicado: (2022)

Importance of hypoglycemia on the risk of Alzheimer’s disease in elderly subjects with diabetes mellitus
por: Muratli S, et al.
Publicado: (2015)

Role of glycemic control on hospital-related outcomes in patients with diabetes mellitus undergoing renal transplantation
por: Lamos EM, et al.
Publicado: (2017)

Nomogram for the Risk of Diabetic Nephropathy or Diabetic Retinopathy Among Patients with Type 2 Diabetes Mellitus Based on Questionnaire and Biochemical Indicators: A Cross-Sectional Study
por: Shi R, et al.
Publicado: (2020)

Vildagliptin and its role in the treatment of diabetes mellitus
por: Yury Shavkatovich Khalimov
Publicado: (2010)

Mild cognitive decline in type 2 diabetes mellitus patients – risk factors and pathogenesis: role of DPP4 activity and future possible therapeutic targets
por: Gul O, et al.
Publicado: (2019)

Classic Type 1 Diabetes Mellitus and Fulminant Type 1 Diabetes Mellitus: Similarity and Discrepancy of Immunological Characteristics and Cytokine Profile
por: Ying L, et al.
Publicado: (2021)

Prevalence and Factors Associated with Microalbuminuria in Pediatric Patients with Type 1 Diabetes Mellitus at a Large Tertiary-Level Hospital in Botswana
por: Ramaphane T, et al.
Publicado: (2021)

The Prevalence and Control of Type 2 Diabetes Mellitus in Residents of a Rural Town, Shandong Province, China
por: Wei M, et al.
Publicado: (2021)

Clinical and psychological aspects of hypoglycemia in patients with diabetes mellitus
por: Olga Georgievna Mel'nikova, et al.
Publicado: (2010)

Plasma Adipsin as a Biomarker and Its Implication in Type 2 Diabetes Mellitus
por: Tafere GG, et al.
Publicado: (2020)

Cross-Sectional Analysis of the Involvement of Interleukin-17A in Diabetic Retinopathy in Elderly Individuals with Type 2 Diabetes Mellitus
por: Liu F, et al.
Publicado: (2021)

The value of patient-reported outcomes in patients with type 2 diabetes mellitus receiving insulin therapy: assessment of quality of life and hypoglycemia problems
por: Tat'yana Ivanovna Ionova, et al.
Publicado: (2015)

Gliptins vs. Milk-derived Dipeptidyl-Peptidase IV Inhibiting Biopeptides: Physicochemical Characterization and Pharmacokinetic Profiling
por: Jorge Andrés Barrero, et al.
Publicado: (2021)

Association Between Abnormal Glycemic Phenotypes and Microvascular Complications of Type 2 Diabetes Mellitus Outpatients in China
por: Liu G, et al.
Publicado: (2020)

Khat Chewing and Type 2 Diabetes Mellitus
por: Badedi M, et al.
Publicado: (2020)